Our research firstly demonstrated that Baicalein decreased phosphorylation of Akt at T-308 through targeting NEDD9-dependent PDK1 expression, but the target of Baicalein on the suppression of p-AKT at S-473 in pancreatic cancer cells requires further exploration. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.